Hermes Surpasses Expectations with a 17% Surge in First-Quarter Sales 
Why is the London Stock Exchange losing out to the US 
Mercedes Launches 2025 G-Class Electric with Four Motors and Revolutionary Tank Turns 
Family farms are fast disappearing: our research shows how young generations can take them up successfully 
Boeing Experiences Quarterly Revenue Drop Amid Production Challenges, Beat Expectations 
LG Energy Solution to Combat Infringement By Launching Licensing Business for Battery Patents 
Tesla Cybertruck Hits 1,000-Unit Weekly Production Amid Q1 Financial Shortfalls 
How marketing classes can rescue ‘ugly produce’ from becoming food waste 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Mercedes-Benz to Release Luxury Electric Van in China 
LATAM Airlines Abandons Plans to Acquire Boeing B737 Planes Amid Gol Bankruptcy 
Volvo Cars Projects Robust Demand Despite Financial Hiccups in Q1 
If plastic manufacturing goes up 10%, plastic pollution goes up 10% – and we’re set for a huge surge in production 
Tesla Model 3 Performance Eligible for $7,500 Tax Credit, Launches at $53K 
PepsiCo Surpasses $18 Billion Revenue Expectations Amid Strong International Demand 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
Tesla Nears FSD Licensing Deal with Major Automaker, Hits 1.3 Billion Milestone 
BOTHELL, Wash., Sept. 08, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that data from Phase 2b and Phase 1 clinical trials of ALD403 supporting development for the prevention of migraine, and preclinical data from a case study of ALD403 and other CGRP-antibodies will be presented at the upcoming 5th European Headache and Migraine Trust International Congress (EHMTIC 2016) on September 15-18, 2016 in Glasgow, U.K.
- Poster presentation: “Randomized, Double-Blind, Placebo-Controlled Trial of ALD403, an Anti-CGRP Peptide Antibody in the Prevention of Chronic Migraine”
Poster #: EHMTC-0410
Session Title: Poster Discussion Session A
Session Date: Friday, September 16, 2016
Session Time: 1:00 am – 12:30 pm BST
- Poster presentation: “A Multiple-Dose, Phase I Placebo-Controlled, Randomized Study of ALD403, An Anti-CGRP Antibody, Administered Every 3-Months via IV, SC, or IM”
Poster #: EHMTC-0397
Session Title: Poster Discussion Session A
Session Date: Friday, September 16, 2016
Session Time: 11:00 am – 12:30 pm BST
- Poster presentation: “Characterization of the Binding of Three Anti-CGRP Antibodies Effective in Preventing Migraine: A Comparative Case Study of ALD403, LY-2951742, TEV-48125”
Poster #: EHMTC-0359
Session Title: Poster Discussion Session E
Session Date: Saturday, September 17, 2016
Session Time: 6:30 pm – 7:30 pm BST
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, ALD403, is being evaluated for migraine prevention. ALD403 is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Todd Davenport, Ph.D. Russo Partners, LLC (212) 845-4271 (212) 845-4235 [email protected] [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals (425) 408-8032 [email protected]
